LTBR and neoplasm: Whether continued LTβR treatment in the absence of immune activation following treatment cessation of CTLA4 blockade + LTβR agonist is sufficient to maintain TA-HEVs and their lymphocyte aggregates which drive control of tumour growth was not determined in this work.